We are live on ! Find out more
HTGM

HTG Molecular Diagnostics, Inc. Common Stock

Delisted

HTGM was delisted on the 14th of June, 2023.

23 hedge funds and large institutions have $7.34M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more capital invested

Capital invested by funds: $5.13M → $7.34M (+$2.21M)

18% less funds holding

Funds holding: 2823 (-5)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $18K

Holders
23
Holders Change
-5
Holders Change %
-17.86%
% of All Funds
0.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
5
Reduced
8
Closed
12
Calls
Puts
$18K
Net Calls
-$18K
Net Calls Change
-$22K

HTGM Hedge Fund Activity: Q4 2020 in Review

23 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2020, worth a combined $7.34M — up 43% from $5.13M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of HTGM and 7 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.

The largest buyer was Cowen Prime Advisors, adding an estimated $1.69M. The largest seller was Perkins Capital Management, exiting entirely with an estimated $802K sold.

  • 23 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2020, down from 28 in Q3 2020.
  • Funds reported $7.34M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2020, up 43% quarter-over-quarter.
  • 7 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2020 and 12 closed out, a net change of -5 holders.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2020 was Cowen Prime Advisors, an estimated $1.69M added.
  • The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2020 was Perkins Capital Management, an estimated $802K sold.

Based on aggregated 13F filings for Q4 2020.